In addition to warfarin, the family of vitamin K antagonist (VKA) oral anticoagulants includes acenocoumarol, phenprocoumon, phenindione and fluindione.
Owing to these advantages, international AF guidelines now recommend NOACs as the first-choice treatment or a viable alternative to VKAs in patients with AF at increased risk of stroke (excluding those with a mechanical heart valve or rheumatic mitral stenosis). 4, 5 With increasing use of NOACs in clinical practice, 6 the real-world evidence (RWE)
of their effectiveness and safety relative to warfarin rapidly accumulates, [7] [8] [9] [10] broadly confirming the results of NOAC landmark trials (see ►Table 1).
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Although warfarin is the most commonly used VKA worldwide, in some countries other VKAs are more often prescribed (e.g. acenocoumarol in Spain or Germany, phenprocoumon in Germany, Austria, Denmark, Switzerland, the Netherlands and Brazil, and fluindione in France), 12 and there are clinically relevant differences among these drugs. 
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Although the observations reported by Hohnloser et al were confirmed in two pre-specified sensitivity analyses, reflecting their robustness to the various model assumptions, 14 the RWE gathered from post-approval observational studies should always be interpreted with caution, taking into account their numerous limitations arising from the 
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